{'fraction_non_alphanumeric': 0.040123456790123455, 'fraction_numerical': 0.0257201646090535, 'mean_word_length': 5.359477124183006, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Response to Comment on Rubino et al. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care 2016;39:861–877

On behalf of the 48 coauthors from our article reporting the findings and recommendations of the 2nd Diabetes Surgery Summit (DSS-II) (1), we sincerely thank Aberle and Goke (2) for their insightful comments about the consideration of sodium–glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes (T2D) shortly after bariatric/metabolic surgery.

The DSS-II was a consensus development conference, culminating a year-long effort to generate new guidelines for the use of “bariatric” operations to expressly treat T2D (i.e., “metabolic surgery”), including among patients not obese enough to qualify for surgery according to traditional BMI-based criteria. Among our 32 position statements, which all had a high consensus rate, one recommendation endorsed the usage …